Skip to main content
. Author manuscript; available in PMC: 2016 May 17.
Published in final edited form as: Vaccine (Auckl). 2016 May 4;6:9–23. doi: 10.2147/VDT.S85545

Table 2. F. novicida-based live attenuated vaccines.

Vaccine strain (F. novicida) Growth medium Animal model Sex Vaccine dose (route) Ft LVS challenge % protection (dose, route) Ft SchuS4 challenge % protection (dose, route) References
iglB: fopC TSB C57BL/6 NA 103 CFU (oral) 80% (3.5×104 CFU, IN) ND 138
IglD TSB CDM BALB/c NA 9.7×108 CFU (IN) ND 0% (103 CFU, IN) 139
Fischer rats (344) F 105 CFU (IT) ND 100% (104 CFU, IT)
NHP M/F 108 CFU (BR) ND 83% (103 CFU, aerosol)
iglB TSB Fischer rats (344) F 107 CFU (oral or IT) ND 50% (∼104 CFU, oral or IT) 140
iglB:fljB TSB BALB/c NA 103 CFU (oral) 83% (8.5×104 CFU, IN) ND 141
Fischer rats (344) NA 107 CFU (oral) ND 83% (104, IT)

Abbreviations: F. novicida, Francisella novicida; Ft, Francisella tularensis; LVS, live vaccine strain; TSB, tryptic soy broth medium; NA: not available; IN, intranasal; ND, not determined; CDM, Chamberlain's defined medium; F, female; IT, intrathecal; NHP, nonhuman primate (cynomolgus macaque); M, male; BR, bonchoscopy route.